calendardigital-marketingit-solutionslocation-dotlogo-footertech-journal-logo-footerweb-development

Open filters Close filters

BTLJ Blog
October 14th, 2010
In Teva v. Eisai, the Federal Circuit held that a subsequent Paragraph IV filer has standing when a patent listed in the Orange Book causes a delay in the triggering of a first filer’s exclusivity period and prevents the subsequent filer from bringing a generic drug to market. The Hatch-Waxman ...